FDA: Mushrooms Recalled Nationwide Over Listeria Concerns
Listeria is a bacteria that poses particular health risks to vulnerable populations like pregnant people, the elderly, and the immunocompromised.
See below for recall details and impacted lots.
Ironically, a mushroom recall is coinciding with the return of The Last of Us. Thankfully, Harvest NYC Inc's enoki mushroom packages won't turn you into a flesh-eating zombie if you eat them. However, the fungi could be contaminated with listeria and cause potentially serious infections in susceptible populations like young children, elderly people, or those with weakened immune systems, the Food and Drug Administration (FDA) said.
Keep reading to learn the specifics of the mushroom recall and what to do if you have the flagged produce on-hand.
The recalled enoki mushrooms were distributed to retailers nationwide. The mushroom variety is usually white in color and long and slim in shape, with small button-like caps. If you believe you have impacted product, do not eat it.
The specific recalled product comes in a 200-gram green plastic package (as shown here) marked with the following identification information:
UPC: 6975730520101
Distributed by: Hofood99 Inc. at 21903 56th Ave Oakland Gardens, NY
The listeria contamination was discovered after samples were collected from a store in Buffalo, New York, and analyzed by the New York State Department of Agriculture and Markets Food Laboratory, which subsequently tested positive for the bacteria. At the time of publication, no related illnesses have been reported.
Listeria monocytogenes (L. monocytogenes) is a type of disease-causing bacteria that may be found in soil, water, sewage, rotting vegetation, and animals, according to FDA, and can thrive in unsanitary food production conditions. It's usually transmitted in manufacturing when food is harvested, processed, prepared, packed, transported, or stored.
In healthy people, infection may only cause short-term symptoms like high fever, headache, stiffness, nausea, abdominal pain, and diarrhea. However, it may cause miscarriages and stillbirths among pregnant women. If the infection spreads beyond the intestines, it may cause neurological symptoms like confusion, loss of balance, convulsions, and can be life-threatening.
If you purchased a recalled package of enoki mushrooms between January 11 and January 31, 2025, the FDA urges you to destroy the goods immediately or return them to their place of purchase for a full refund. If you have questions, you can contact the company at (718) 596-0777.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
an hour ago
- Epoch Times
FDA Approves Weight Loss Drug Wegovy for Liver Disease
The Food and Drug Administration has approved a weight loss drug called Wegovy for a liver disease, the agency announced on Aug. 18. Wegovy is now approved for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that impacts approximately 6 percent of American adults, the FDA said in a statement.
Yahoo
an hour ago
- Yahoo
Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease
Key Takeaways Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious disease of the liver. Wegovy can be used for patients suffering from noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH. The company said MASH affects one in three overweight or obese people, including 22 million in the U.S. U.S.-listed shares of Novo Nordisk (NVO) gained 4% in premarket trading after the Food and Drug Administration (FDA) approved the pharmaceutical firm's popular weight-loss drug, Wegovy, to treat a serious liver disease. The Denmark-based firm reported the FDA said Wegovy could be used for adults suffering from noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, who have moderate to advanced liver fibrosis, along with eating less and exercising more. Novo Nordisk Chief Scientific Officer Martin Holst Lange noted that the decision means Wegovy is the only GLP-1 obesity medicine that has received regulatory approval to treat MASH. He explained that one in three overweight or obese people suffer from it, with some 22 million Americans among them. He added that Wegovy not only stopped the disease activity, it also reversed liver damage. The company announced that Wegovy would be available immediately in the U.S. for the treatment of MASH. The approval is welcome news to Novo Nordisk investors, who have seen the U.S.-listed shares slump as competition from others in the weight-loss category has siphoned away sales of Wegovy. At the close of trading Friday, the shares were down nearly 40% year-to-date. Read the original article on Investopedia
Politico
an hour ago
- Politico
HHS embraces AI
EXAM ROOM The Department of Health and Human Services has emerged as the leader in artificial intelligence use among all federal agencies. In 2024, HHS reported 116 different ways to use AI for generating content and responses — up from just seven the year before, according to a report from the Government Accountability Office, which monitors agencies for Congress. The GAO reported 271 different AI tools in use last year. A recent analysis by the Bipartisan Policy Center, a think tank in Washington, reveals how three HHS agencies have implemented AI. Notably, they're largely using chatbots to help them work more efficiently. The Centers for Disease Control and Prevention: In 2023, the CDC launched ChatCDC, a bot built on OpenAI's large language models that can summarize meeting minutes, internal documents and studies. It also uses the bot to write code for data analysis. The CDC is experimenting with an updated version that uses more internal documents, but as of January, it hadn't yet been released. The Food and Drug Administration: The FDA has launched a chatbot to help staff respond to emails, summarize meeting minutes and perform a wide variety of basic tasks. While FDA Commissioner Marty Makary has promised faster regulatory review turnaround, staff have argued that the tool is prone to mistakes and incapable of assisting with the review process. The FDA has also experimented with using AI for an array of tasks, including labeling drugs and looking for data patterns and anomalies. The Centers for Medicare and Medicaid Services: CMS uses AI to prevent and detect fraud, waste and abuse and analyze prescription drug costs. The takeaway: HHS continues to lead the way for AI use. Health Secretary Robert F. Kennedy Jr. has said he sees digital technology and AI as key tools for improving health care outcomes and reducing costs. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Sen. Marsha Blackburn (R-Tenn.) is calling for an investigation into Meta following reporting that the company allowed its chatbots to 'engage a child in conversations that are romantic or sensual.' Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. INFLUENCERS A newly launched psychedelic medicine foundation wants to become the 'American Cancer Society of ibogaine access.' Mission Within Foundation, which officially launched today, plans to use the $2 million in funding it has secured from private donors and foundations to promote the psychedelic drug ibogaine, derived from an African shrub, as a mental health treatment. The Drug Enforcement Administration classifies ibogaine as a Schedule I drug with no currently acceptable medical use and a high risk of abuse. It can pose heart risks and has been linked to about two dozen deaths in recent decades. The foundation plans to lobby for safe and legal access to ibogaine treatment in the U.S. and offer fully funded psychedelic therapy retreats to veterans and frontline workers with post-traumatic stress disorder, traumatic brain injuries, depression and addiction. It will also team up with the Dell Medical School at the University of Texas on three ibogaine research studies. Who's who: Dr. Martín Polanco, who runs The Mission Within, a psychedelic medicine clinic in Tijuana, Mexico, is one of the foundation's founders. He's treated more than 5,000 people with traumatic brain injuries and mental health conditions like PTSD, including many veterans, using ibogaine and the psychedelic drug 5-MeO-DMT, a desert toad secretion. Polanco has the ear of Reps. Jack Bergman (R-Mich.) and Lou Correa (D-Calif.), co-founders of the Congressional Psychedelics Advancing Therapies Caucus, who've been working in Washington to advance psychedelic medicine. Correa traveled to Polanco's clinic in Tijuana last year to talk with him in person and see whether his work justified further research on the drugs in the U.S. The foundation, which is also advocating for psychedelic medicine more broadly, is supporting Correa and Bergman's Innovative Therapies Centers of Excellence Act, which the pair introduced in April. The bill seeks $30 million for Veterans Affairs Department research on psychedelic therapies and would create five centers of excellence to research alternative treatments for veterans. What's next: Texas Gov. Greg Abbott, a Republican, signed a law in June putting $50 million in state funding toward clinical trials of ibogaine as a mental health treatment. And the state budget Arizona's Democratic governor, Katie Hobbs, signed into law the same month included a commitment of $5 million for studying ibogaine. Mississippi plans to hold a joint hearing of the House and Senate Public Health and Human Services committees on ibogaine on August 28.
